Sarpogrelate hydrochloride, a selective 5-HT2A antagonist, improves vascular function in patients with peripheral arterial disease

Journal of Cardiovascular Pharmacology

Volumn 49, Issue 4, 2007, Pages 221-227

  Miyazaki, Masanori ^a   Higashi, Yukihito ^a   Goto, Chikara ^a   Chayama, Kazuaki ^a   Yoshizumi, Masao ^a   Sanada, Hiroaki ^a   Orihashi, Kazumasa ^a   Sueda, Taijiro ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

Author keywords

5 HT 2A antagonist; Nitroglycerin; Peripheral arterial disease; Reactive hyperemia

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLYCERYL TRINITRATE; METFORMIN; SARPOGRELATE; SEROTONIN 2A ANTAGONIST; SULFONYLUREA;

AGED; ARTERY DISEASE; ARTICLE; CARDIOVASCULAR FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIUM; FEMALE; FOLLOW UP; FOREARM BLOOD FLOW; HUMAN; HYPEREMIA; LEG BLOOD FLOW; MALE; PLETHYSMOGRAPHY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ARTERIAL OCCLUSIVE DISEASES; BIOLOGICAL MARKERS; ENDOTHELIUM, VASCULAR; FEMALE; FOLLOW-UP STUDIES; FOREARM; HUMANS; HYPEREMIA; LEG; MALE; NITROGLYCERIN; PERIPHERAL VASCULAR DISEASES; RECEPTOR, SEROTONIN, 5-HT2A; REGIONAL BLOOD FLOW; RESEARCH DESIGN; SEROTONIN ANTAGONISTS; SUCCINATES; TIME FACTORS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 34247203227     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/FJC.0b013e3180325af3     Document Type: Article

References (53)

1. Ress DD, Palmer RMJ, Moncada S. Role of endothelium-derived nitric oxide in the regulation of blood pressure. Proc Natl Acad Sci USA. 1989;86:3375-3378.
2. Vane JR, Anggard EE, Botting RM. Regulatory functions of the vascular endothelium. N Engl J Med. 1990;323:27-36.
3. Vallance P, Collier J, Moncada S. Effect of endothelium-derived nitric oxide on peripheral arteriolar tone in man. Lancet. 1989;2:997-1000.
4. Vanhoutte PM. Endothelium and control of vascular function: state of the art lecture. Hypertension. 1989;13:658-667.
5. Ross R. The pathogenesis of atherosclerosis. N Engl Med. 1986;314:488-500.
6. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326:381-386.
7. Leng GC, Fowkes FG, Lee AJ, et al. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study. Br Med J. 1996;313:1440-1444.
8. Zheng ZJ, Scharrett AR, Chambless LE, et al. Associations of ankle brachial index with clinical coronary heart disease, stroke and preclinical carotid and popliteal atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 1997;131:115-125.
9. Newman AB, Shemanski L, Manolio TA, et al. Ankle-arm index as a predictor of cardiovascular disease and mortality in the Cardiovascular Health Study. The Cardiovascular Health Study Group. Arterioscler Thromb Vasc Biol. 1999;19:538-545.
10. Liao JK, Bettmann MA, Sandor T, et al. Differential impairment of vasodilator responsiveness of peripheral resistance and conduit vessels in humans with atherosclerosis. Circ Res. 1991;68:1027-1034.
11. Harris LM, Faggioli GL, Shah R, et al. Vascular reactivity in patients with peripheral vascular disease. Am J Cardiol. 1995;76:207-212.
12. Brevetti G, Silvestro A, Schiano V, et al. Endothelial dysfunction and cardiovascular risk prediction in peripheral arterial disease: additive value of flow-mediated dilation to ankle-brachial pressure index. Circulation. 2003;108:2093-2098.
13. Bode-Boger SM, Boger RH, Alfke H, et al. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation. 1996;93:85-90.
14. Komori K, Matsumoto T, Ishida M, et al. Enhancement of nitric oxide production after arterial reconstruction in patients with arteriosclerosis obliterans. J Vasc Surg. 1997;26:657-662.
15. Brendle DC, Joseph LJ, Corretti MC, et al. Effects of exercise rehabilitation on endothelial reactivity in older patients with peripheral arterial disease. Am J Cardiol. 2001;87:324-329.
16. Hoyer D, Clarke DE, Fozard JR, et al. International union of pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev. 1999;46:157-201.
17. 2A receptor and its antagonists in the cardiovascular system. Pharmacol Ther. 2004;104:59-81.
18. Golino P, Piscione F, Willerson JT, et al. Divergent effects of serotonin on coronary-artery dimensions and blood flow in patients with coronary atherosclerosis and control patients. N Engl J Med. 1991;324:64-68.
19. Saxena PR, Villalon CM. Cardiovascular effects of serotonin agonists and antagonists. J Cardiovasc Pharmacol. 1990;15:S17-S34.
20. Roth BL, Willins DL, Kristiansen K, et al. 5-hydroxytryptamine 2 family receptors (5-hydroxytryptamine2A, 5-hydroxytryptamine2B, 5-hydroxytryptamine2C): where structure meets function. Pharmacol Ther. 1998;79:231-257.
21. Banes A, Florian JA, Watts SW. Mechanisms of 5-hydroxytryptamine(2A) receptor activation of the mitogen-activated protein kinase pathway in vascular smooth muscle. J Pharmacol Exp Ther. 1999;29:1179-1187.
22. 1B/1D-receptor antagonist GR. Circ Res. 2001;89:1231-1239.
23. Barradas MA, Gill DS, Fonseca VA, et al. Intraplatelet serotonin in patients with diabetes mellitus and peripheral vascular disease. Eur J Clin Invest. 1988;18:399-404.
24. Ito K, Notsu T. Effect of sarpogrelate hydrochloride (MCI-9042) on peripheral circulation of chronic arterial occlusive disease. J Clin Ther Med. 1991;7:1243-1251.
25. Nakamura K, Kariyazono H, Masuda H, et al. Effects of sarpogrelate hydrochloride on adenosine diphosphate- or collagen-induced platelet responses in arteriosclerosis obliterans. Blood Coagul Fibrinolysis. 2001;12:391-397.
26. Hara H, Kitajima A, Shimada H, et al. Antithrombic effect of MCI-9042, a new antiplatelet agent on experimental thrombosis models. Thromb Haemost. 1991;66:484-488.
27. Yamashita T, Kitamori K, Hashimoto M, et al. Conjunctive effects of 5HT2 receptor antagonist, sarpogrelate, on thrombolysis with modified tissue plasminogen activator in different laser-induced thrombosis models. Haemostasis. 2000;30:321-332.
28. Hara H, Osakabe M, Kitajima A, et al. MCI-9042, a new antiplatelet agent is a selective S2-serotonergic receptor antagonist. Thromb Haemost. 1991;65:415-420.
29. Nakamura K, Kariyazono H, Moriyama Y, et al. Effects of sarpogrelate hydrochloride on platelet aggregation, and its relation to the release of serotonin and P-selectin. Blood Coagul Fibrinolysis. 1999;10:513-519.
30. Sharma SK, Zahradka P, Chapman D, et al. Inhibition of serotonin-induced vascular smooth muscle cell proliferation by sarpogrelate. J Pharmacol Exp Ther. 1999;290:1475-1481.
31. Hotta N, Nakamura J, Sumita Y, et al. Effects of the 5-HT2A receptor antagonist sarpogrelate in diabetic patients with complications. Clin Drug Invest. 1999;18:199-207.
32. Takei I, Nakamoto S, Yamauchi Y, et al. Effects of the 5-HT2 receptor antagonist sarpogrelate on diabetic vascular disease. Diabetes Res. 1999;34:239-246.
33. Yamakawa J, Takahashi T, Saegusa S, et al. Effect of the serotonin blocker sarpogrelate on circulating interleukin-18 levels in patients with diabetes and arteriosclerosis obliterans. J Int Med Res 2004;32:166-169.
34. Norgren L, Jawien A, Matyas L, et al. European MCI-9042 Study Group. Sarpogrelate, a 5-hT2A receptor antagonist in intermittent claudication. A phase II European study. Vasc Med 2006;11:75-83.
35. Hayashi T, Sumi D, Matsui-Hirai H, et al. Sarpogrelate HCl, a selective 5-HT2A antagonist, retards the progression of atherosclerosis through a novel mechanism. Atherosclerosis. 2003;168:23-31.
36. Panza JA, Quyyumi AA, Brush JE Jr, et al. Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med. 1990;323:22-27.
37. Higashi Y, Sasaki S, Nakagawa K, et al. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med. 2002;346:1954-1962.
38. Koller M. Results for 74 substances tested for interference with determination of plasma catecholamines by "high-performance" liquid chromatography with electrochemical detection. Clin Chem. 1988;34:947-949.
39. Sanada H, Higashi Y, Goto C, et al. Vascular function in patients with lower extremity peripheral arterial disease: a comparison of functions in upper an lower extremities. Atherosclerosis. 2005;178:179-185.
40. Vanhoutte PM. Endothelial dysfunction and vascular disease. Verh K Acad Geneeskd Belg. 1998;60:251-266.
41. Cocks TM, Angus JA. Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature. 1983;305:627-630.
42. 1D receptor subtype. J Pharmacol Exp Ther. 1990;252:387-395.
43. 2B receptors. Br J Pharmacol. 2000;130:692-698.
44. Mikawa K, Akamatsu H, Nishina K, et al. The effects of sarpogrelate on superoxide production by human neutrophils. Reg Anesth Pain Med. 2000;25:181-186.
45. Waters KJ, Craxford AD, Chamberlain J. The effects of naftidrofuryl (Praxilene) on intermittent claudication. Br J Surg. 1980;67:349-351.
46. Moody AP, Al-Khaffaf HS, Lehert P, et al. An evaluation of patients with severe intermittent claudication and the effect of treatment with Naftidrofuryl. J Cardiovasc Pharmacol. 1984;23:44-47.
47. Drummond M, Davies L. Economic evaluation of drugs in peripheral vascular disease and stroke. J Cardiovasc Pharmacol. 1994;23:S4-S7.
48. Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med. 1999;159:337-345.
49. Higashi Y, Sasaki S, Nakagawa K, et al. A noninvasive measurement of reactive hyperemia that can be used to assess resistance artery endothelial function in humans. Am J Cardiol. 2001;87:121-125.
50. Matsumoto A, Hirata Y, Momomura S, et al. Increased nitric oxide production during exercise. Lancet. 1994;343:849-850.
51. Higashi Y, Sasaki S, Nakagawa K, et al. A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, betablockers, diuretics on reactive hyperemia in patients with essential hypertensions: a multicenter study. J Am Coll Cardiol. 2000;35:284-291.
52. Ghiadoni L, Virdis A, Magagna A, et al. Effect of the angiotensin II type 1 receptor blocker candesartan on endothelial function in patients with essential hypertension. Hypertension. 2000;35:501-506.
53. Wassmann S, Ribaudo N, Faul A, et al. Effect of atorvastatin 80 mg on endothelial cell function (forearm blood flow) in patients with pretreatment serum low-density lipoprotein cholesterol levels <130 mg/dL. Am J Cardiol. 2004;93:84-88.